GRAIL Inc (GRAL) Price & Analysis

Compare

206 Followers

GRAL Stock Chart & Stats

Day’s Range― - ―

52-Week Range$12.33 - $63.99

Previous CloseN/A

Volume371.20K

Average Volume (3M)1.16M

Market Cap

$1.18B

Enterprise Value$265.97M

Total Cash (Recent Filing)$674.58M

Total Debt (Recent Filing)$64.32M

Price to Earnings (P/E)―

Beta2.69

Next Earnings

Aug 12, 2025

EPS Estimate

-3.57

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-3.10

Shares Outstanding35,973,495

10 Day Avg. Volume833,656

30 Day Avg. Volume1,158,114

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.23

Enterprise Value/Revenue2.03

Enterprise Value/Gross Profit-6.42

Enterprise Value/Ebitda-0.47

Forecast

1Y Price Target

$40.50

Price Target Upside23.40% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Market OpportunityA large market opportunity exists for GRAL with a total addressable market exceeding $50 billion.

Strategic PartnershipsNew strategic partnerships with Quest Diagnostics and TRICARE Health Insurance are expected to expand Grail Inc's reach and grow the market ahead of significant study readouts.

Technological AdvantageGRAIL has a first-mover advantage in the multi-cancer early detection (MCED) testing market, driven by its leading generation of clinical data and large addressable market.

Bears Say

Cash Burn ConcernsThe company burned nearly $90 million in cash during 1Q25, which was slightly higher than the analyst's estimate.

Lack Of Near-Term CatalystsA lack of near-term catalysts is currently limiting the potential for immediate stock price growth or significant changes in analyst recommendations.

Regulatory And Reimbursement RisksThere are inherent risks with GRAL's novel technologies from a regulatory and reimbursement perspective that could impact adoption.

GRAIL Inc News

Grail Inc.’s Galleri® Test: A Promising Step in Early Cancer Detection for Medicare

Grail Inc (($GRAL)) announced an update on their ongoing clinical study. Grail Inc. is conducting a study titled...

2d ago

GRAL

Supreme Court keeps element of Obamacare preventive care, Reuters reports

The U.S. Supreme Court has kept a key element of the Obamacare law that helps guarantee that health...

1M ago

Grail Inc.’s REACH Study: Advancing Multi-Cancer Detection in Medicare

Grail Inc (($GRAL)) announced an update on their ongoing clinical study. Grail Inc.’s latest clinical study, officially titled...

1M ago

GRAL

Grail assumed with an Equal Weight at Morgan Stanley

Morgan Stanley assumed coverage of Grail (GRAL) with an Equal Weight rating and a price target of $38,...

1M ago

GRAL

Cautious Optimism for GRAIL Inc: Hold Rating Amid Early Market Position and Future Milestones

Yuko Oku, an analyst from Morgan Stanley, maintained the Hold rating on GRAIL Inc (GRAL – Research Report)....

2M ago

GRAL

Grail reports results from PATHFINDER 2 study

Grail (GRAL) announced positive top-line performance and safety results from the pre-specified analysis of the first 25,578 participants...

2M ago

GRAL

NINGI short Grail, says ‘approval and commercialization all but impossible’

In a recently published report, NINGI Research says it is short Grail (GRAL), arguing that “the company’s overly...

2M ago

GRAL

GRAIL Inc Holds Annual Stockholders Meeting

GRAIL Inc ( ($GRAL) ) has provided an announcement. On May 29, 2025, GRAIL, Inc. held its Annual...

2M ago

GRAL

Grail Inc. Q1 Earnings: Growth Amid Funding Concerns

Grail Inc (($GRAL)) has held its Q1 earnings call. Read on for the main highlights of the call....

3M ago

GRAL

Grail price target raised to $43 from $32 at Canaccord

Canaccord raised the firm’s price target on Grail (GRAL) to $43 from $32 and keeps a Buy rating...

3M ago

GRAL

Grail Inc. Reports Growth and Positive Trial Results

Grail Inc ( ($GRAL) ) has released its Q1 earnings. Here is a breakdown of the information Grail...

3M ago

GRAL

Closing Bell Movers: Exelixis up 6% on earnings beat

In the opening hour of the evening session, U.S. equity futures are little changed, with S&P 500 flat...

3M ago

AEO

Grail reports Q1 EPS ($3.10), consensus ($3.80)

Reports Q1 revenue $31.8M, consensus $35.2M. Cash, cash equivalents, restricted cash and short-term marketable securities totaled $677.9M as...

3M ago

GRAL

Grail Inc options imply 15.2% move in share price post-earnings

Pre-earnings options volume in Grail (GRAL) Inc is 7.1x normal with calls leading puts 8:5. Implied volatility suggests...

3M ago

GRAL

GRAL FAQ

What was GRAIL Inc’s price range in the past 12 months?

GRAIL Inc lowest stock price was $12.33 and its highest was $63.99 in the past 12 months.

What is GRAIL Inc’s market cap?

GRAIL Inc’s market cap is $1.18B.

When is GRAIL Inc’s upcoming earnings report date?

GRAIL Inc’s upcoming earnings report date is Aug 12, 2025 which is in 2 days.

How were GRAIL Inc’s earnings last quarter?

GRAIL Inc released its earnings results on May 13, 2025. The company reported -$3.1 earnings per share for the quarter, beating the consensus estimate of -$3.987 by $0.887.

Is GRAIL Inc overvalued?

According to Wall Street analysts GRAIL Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does GRAIL Inc pay dividends?

GRAIL Inc does not currently pay dividends.

What is GRAIL Inc’s EPS estimate?

GRAIL Inc’s EPS estimate is -3.57.

How many shares outstanding does GRAIL Inc have?

GRAIL Inc has 35,973,495 shares outstanding.

What happened to GRAIL Inc’s price movement after its last earnings report?

GRAIL Inc reported an EPS of -$3.1 in its last earnings report, beating expectations of -$3.987. Following the earnings report the stock price went down -23.315%.

Which hedge fund is a major shareholder of GRAIL Inc?

Currently, no hedge funds are holding shares in GRAL

GRAIL Inc Stock Smart Score

Neutral

Fundamentals

Return on Equity

-62.22%

Trailing 12-Months

Asset Growth

-28.32%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

GRAIL Inc

GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.

GRAIL Inc (GRAL) Earnings & Revenues

Historic Earnings Reports

GRAL Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call presented strong first-quarter results with significant revenue growth and positive trial results, alongside strategic partnerships and market expansion. However, concerns about future funding and uncertainty around key trial results present challenges.View all GRAL earnings summaries

GRAL Stock 12 Month Forecast

Average Price Target

$40.50

▲(23.40% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"12":"$12","31":"$31","50":"$50","21.5":"$21.5","40.5":"$40.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":43,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$43.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":40.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$40.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$38.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[12,21.5,31,40.5,50],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,49.23,48.75076923076923,48.27153846153846,47.79230769230769,47.31307692307692,46.83384615384615,46.354615384615386,45.87538461538461,45.396153846153844,44.91692307692308,44.43769230769231,43.958461538461535,43.47923076923077,{"y":43,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,49.23,48.558461538461536,47.886923076923075,47.215384615384615,46.543846153846154,45.87230769230769,45.200769230769225,44.529230769230765,43.857692307692304,43.18615384615384,42.51461538461538,41.84307692307692,41.17153846153846,{"y":40.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,49.23,48.36615384615384,47.50230769230769,46.638461538461534,45.77461538461538,44.910769230769226,44.04692307692308,43.183076923076925,42.31923076923077,41.45538461538462,40.59153846153846,39.72769230769231,38.863846153846154,{"y":38,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":16.64,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":14.11,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.25,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.25,"date":1727740800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":13.55,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":18.73,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":17.85,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":30.28,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":38.56,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":25.1,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.49,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.5,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.23,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >